title: EPIC Early Detection of Ovarian Cancer.
abstract: CA125 dominated performance for ovarian cancer early detection among four serum biomarkers evaluated in EPIC study prediagnostic serum, rising on average 3 years prior to detection. Adding HE4 provided only marginal improvement. This natural history supports annual testing for early detection and highlights the importance of biomarker discovery complementing CA125. Clin Cancer Res; 22(18); 4542-4. ©2016 AACRSee related article by Terry et al., p. 4664.
authors.affiliation: Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. sskates@partners.org.
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Skates
mesh_terms: D014408:Biomarkers, Tumor; D016022:Case-Control Studies; D055088:Early Detection of Cancer / Q000379:methods; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000097:blood* / Q000175:diagnosis*
chemical_list: D014408:Biomarkers, Tumor